Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Moodys
Merck
Boehringer Ingelheim
Healthtrust
Queensland Health
Colorcon
Chubb
AstraZeneca
US Army

Generated: August 18, 2017

DrugPatentWatch Database Preview

DUAVEE Drug Profile

« Back to Dashboard

What is the patent landscape for Duavee, and when can generic versions of Duavee launch?

Duavee is a drug marketed by Wyeth Pharms Pfizer and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-two patent family members in forty countries.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Summary for Tradename: DUAVEE

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list6
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DUAVEE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DUAVEE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: DUAVEE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,538 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation► Subscribe
6,835,729 2-phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,132,4172-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,232,307 Tissue selective compounds in the treatment of ovarian cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DUAVEE

Country Document Number Estimated Expiration
Hungary9700777► Subscribe
Austria206701► Subscribe
Portugal802183► Subscribe
Japan2007532560► Subscribe
Japan2009035535► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DUAVEE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00035Denmark► Subscribe
0416Netherlands► Subscribe300416, 20170415, EXPIRES: 20220414
2009007,C0802183Lithuania► SubscribePRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
4Finland► Subscribe
C/GB09/045United Kingdom► SubscribePRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Citi
Cantor Fitzgerald
US Army
Novartis
Fish and Richardson
Julphar
Dow
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot